Asia Pacific Cell and Gene Therapy Market Size, Share, Trends, and Forecast to 2031
Asia Pacific Cell and Gene Therapy Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type [Cell Therapy (Allogeneic, Autologous, Viral Vectors), and Gene Therapy (Non-viral Vectors and Viral Vectors]), Service (Process Development, cGMP Manufacturing, Regulatory Services, and Bioassay Services), Scale (Pre-commercial or R&D Manufacturing and Commercial Scale Manufacturing), Service Providers (CDMOs and CMOs), Transfection Reagents (Polymer-based Transfection Reagents, Lipid-based Transfection Reagents, Viral Transduction Enhancers, and Other Transfection Reagents), End User (Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, and Academic and Research Institutes), and Country
- Report Date : Dec 2025
- Report Code : TIPRE00041707
- Category : Life Sciences
- Status : Published
- Available Report Formats :
- No. of Pages : 229
The Asia Pacific cell and gene therapy market is projected to reach US$ 8.98 billion by 2031 from US$ 1.51 bllion in 2024 at a CAGR of 29.1% during 2025–2031.
Asia Pacific Cell and Gene Therapy Market AnalysisThe primary factors driving market growth include the increasing prevalence of chronic and genetic diseases, supportive government initiatives, and the rapid popularity of outsourcing cell and gene therapy manufacturing. Expansion of local manufacturing capabilities is expected to create ample opportunities for the Asia Pacific cell and gene therapy market in the coming years.
Asia Pacific Cell and Gene Therapy Market OverviewChina, Japan, South Korea, India, and Australia are among the major investors in biomanufacturing, clinical trials, and the establishment of quality control laboratories. The countries are actively promoting the use of innovative technologies, including advanced gene editing, cell-sheet therapies, automation, and AI-enabled quality control. These advancements accelerate the development of therapies and enhance manufacturing stability. The need for treatments for cancer, rare diseases, and genetic disorders drives the demand for these therapies. Additionally, there is an increasing awareness and acceptance of regenerative and precision medicine approaches in the region.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Asia Pacific Cell and Gene Therapy Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Asia Pacific Cell and Gene Therapy Market Drivers and OpportunitiesCustomize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Asia Pacific Cell and Gene Therapy Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Drivers:
- Rising Prevalence of Genetic Diseases: The increasing prevalence of inherited disorders is leading to the widespread use of carrier testing to inform reproductive decisions and reduce the risk of future health problems.
- Increasing Personalized/Preventive Healthcare Focus: The growth of personalized medicine and preventive care is a positive sign that patients and doctors will utilize carrier testing to identify genetic risks beforehand and plan for reproduction.
- Favorable Government & Regulatory Support: Encouraging policies, screening recommendations, and investments in genetic services are enabling more people to access carrier testing, whether due to the healthcare system's standardization or integration of routine healthcare.
Market Opportunities:
- Strategic Initiatives by Companies: Companies involved in the cell and gene therapy market focus on collaborations, expansions, agreements, partnerships, new launches, and other strategic developments. These strategic initiatives help them improve sales, expand geographic reach, and enhance their capacity to cater to a large customer base.
- Expansion of Local Manufacturing Capabilities: The region is witnessing a transformative surge in CGT manufacturing, fueled by strategic investments and technology transfers that localize production and accelerate access to innovative treatments. This expansion addresses global supply chain vulnerabilities while fostering indigenous innovation, particularly in oncology and rare diseases.
- Rising Investments in R&D and Clinical Trials: The region is emerging as a powerhouse in CGT, fueled by robust investments in research and development and a proliferation of clinical trials.
The Asia Pacific cell and gene therapy market is segmented into various categories to provide a clearer understanding of its operations, growth potential, and current trends. Below is the standard segmentation approach used in industry reports:
By Type:
- Cell Therapy: Cell therapy demand is driven by substantial research investment, expanding manufacturing capacity, and increasing adoption of regenerative and oncology treatments across the region.
- Gene Therapy: Gene therapy advances are supported by improved regulations, rising clinical trial activity, and a growing focus on treating rare genetic and inherited diseases in the region.
By Service:
- Process Development: Process development is about finding the most effective ways to scale up production that are of high quality and can be implemented in a factory to support the expanding clinical pipelines in the region and the commercialization of advanced therapies.
- cGMP Manufacturing: cGMP manufacturing involves producing cell and gene therapies in a compliant and reliable manner, supported by regional facilities that are growing, and the investment being made in a high-standard biomanufacturing infrastructure.
- Regulatory Services: Regulatory services are the means by which companies are guided through Asia Pacific approval routes by staff assisting in the preparation of documentation, ensuring compliance, and facilitating the rapid development of advanced therapeutic products.
- Bioassay Services: Bioassay services are the means by which analytical testing is conducted for potency, safety, and functionality, thereby ensuring consistent quality and regulatory compliance for cell and gene therapies produced locally.
By Scale:
- Pre-commercial/R and D Manufacturing: R&D manufacturing is a means of development that is supported by the early stages, and it involves small-batch production, which is flexible and rapid prototyping, and optimization of emerging therapies in the region is enabled.
- Commercial Scale Manufacturing: The emphasis in commercial manufacturing is on producing large-scale, compliant products that the expanding regional facilities support. Thus, a reliable supply can be maintained for approved therapies throughout APAC.
By Service Providers:
- CDMOs: CDMOs offer the integration of development and the provision of manufacturing support that results in a faster scale-up, alignment with regulations, and end-to-end services being available for regional therapy innovators.
- CMOs: CMOs provide the specialized manufacturing capacity that allows companies to release themselves from infrastructure burdens while meeting the rising demand for clinical and commercial-grade therapies in the region.
By Transfection Reagents:
- Polymer-based Transfection Reagents: Polymer-based reagents can support efficient gene delivery if the processes are scalable and cost-effective. Such methods are suitable for high-throughput research and early-stage therapy development.
- Lipid-based Transfection Reagents: Lipid-based reagents are an efficient way to deliver nucleic acids, and that is why they are heavily used in the development of therapeutics, since there is strong compatibility with cell and gene engineering.
- Viral Transduction Enhancers: The use of viral transduction enhancers results in the improvement of vector uptake and expression, which makes manufacturing more productive and consistent for complex cell and gene therapy workflows.
- Other Transfection Reagents: This category comprises the support given by the novel materials, emerging delivery tools, and enabling technologies to innovation and process efficiency throughout the therapy development spectrum.
By End User:
- Contract Research Organizations
- Pharmaceutical and Biopharmaceutical Companies
- Academic and Research Institutes
By Geography:
- Asia Pacific
Market Report Scope
Asia Pacific Cell and Gene Therapy Market Share Analysis by GeographyThe increasing prevalence of chronic and genetic diseases, supportive government initiatives, and the rapid popularity of outsourcing cell and gene therapy manufacturing drive the market growth.
Below is a summary of market share and trends by region:
1. Asia Pacific
- Market Share: Fastest-growing region with rising market shares every year
- Key Drivers: The adoption of cell and gene therapy is progressing rapidly due to continuous healthcare investment, growing awareness among the middle class, and increasing accessibility of genomic technologies.
- Trends: Improvements in access to genomics and increased consumer awareness
High Market Density and Competition
Competition is intense due to established players such as WuXi AppTec Co Ltd and Lonza Group AG. Regional and niche providers, including CellVec Pte Ltd and Avance Clinical Pty Ltd, add to the competitive landscape across different regions.
This high level of competition urges companies to stand out by offering:
- Advanced products
- Value-added services such as customization and sustainable solutions
- Competitive pricing models
- Compliance with regulatory guidelines
Opportunities and Strategic Moves
- Companies are investing in research and development, driving innovation in detection technologies. These investments improve the sensitivity and specificity, addressing specific genetic health issues in different countries.
- Manufacturers will likely focus on local production to cut costs and strengthen supply chains, especially in high-volume markets such as India.
- OBiO Technology
- Genepeutic Bio
- Jubilant Biosys Ltd
- Cyto‑Facto Inc.
- BioCell Innovations Pte Ltd
- Taiwan Cell Manufacturing Company (TCMC)
- Aragen Life Sciences
- Hetero Labs
- BioXcellence
- Catalent, Inc.
- New Australian Collaboration to Advance Gene and Cell Therapy Sector: Viral Vector Manufacturing Facility (VVMF) and Cell Therapies co-signed a Memorandum of Understanding (MoU) to explore strategic collaboration opportunities aimed at strengthening the onshore development and manufacture of Advanced Therapy Medicinal Products (ATMPs).
The "Asia Pacific cell and gene therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
- Asia Pacific cell and gene therapy market size and forecast at the regional and country levels for all the key market segments covered under the scope
- Asia Pacific cell and gene therapy market trends, and market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Asia Pacific cell and gene therapy market analysis covering key market trends, regional and country framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Asia Pacific cell and gene therapy market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The market is estimated to register a CAGR of 29.1% during the forecast period.
The Asia Pacific cell and gene therapy market is projected to reach a value of US$ 8.98 billion by 2031.
WuXi AppTec (WuXi Advanced Therapies), Lonza, Samsung Biologics, AGC Biologics, GenScript Biotech, Syngene International Ltd, Novotech, SK pharmteco Inc, CMIC Group, Porton Pharma Solutions Ltd are among the key players operating in the market.
The increasing prevalence of chronic and genetic diseases, supportive government initiatives, and the rapid popularity of outsourcing cell and gene therapy manufacturing drive market growth.
China dominated the market in 2024.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. Asia Pacific Cell and Gene Therapy Market Landscape
4.1 Overview
4.2 Value Chain Analysis
4.2.1 Cell and Gene Therapy Market – Value Chain Analysis
4.2.2 Raw Material Suppliers / Components
4.2.3 Manufacturers Process / Technology
4.2.4 Distribution Landscape
4.2.5 End User
4.2.6 Level of Integration
4.3 Supply Chain Analysis
4.3.1 List of Service Providers
4.3.2 List of Potential Customers
4.4 Porter’s Five Force Analysis
4.4.1 Bargaining Power of Suppliers:
4.4.2 Bargaining Power of Buyers:
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitutes:
4.4.5 Competitive Rivalry:
4.5 PEST Analysis
4.6 Impact of Artificial Intelligence (AI)
4.7 Product/Technology Roadmap
4.8 Sustainability and ESG Trends
4.8.1 Environmental Trends
4.8.2 Social Trends
4.8.3 Governance Trends
4.9 Patent Analysis
4.10 Regulatory Framework and Pipeline Analysis
4.10.1 Pipeline Analysis
4.11 Import-Export Analysis
5. Competitive Landscape
5.1 Heat Map Analysis by Key Players
5.2 Company Market Share Analysis, 2024
5.3 Company Market Share Analysis by Top 5 Players, 2024
6. Asia Pacific Cell and Gene Therapy Market – Key Market Dynamics
6.1 Asia Pacific Cell and Gene Therapy Market – Key Market Dynamics
6.2 Market Drivers
6.2.1 Increasing Prevalence of Chronic and Genetic Diseases
6.2.2 Supportive Government Initiatives
6.2.3 Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing
6.3 Market Restraints
6.3.1 High Development and Treatment Costs
6.3.2 Complex and Lengthy Regulatory Processes
6.3.3 Shortage Of Skilled Professionals and Infrastructure
6.4 Market Opportunities
6.4.1 Strategic Initiatives by Companies
6.4.2 Expansion of Local Manufacturing Capabilities
6.4.3 Rising Investments in R&D and Clinical Trials
6.5 Future Trends
6.5.1 Surging Adoption of CRISPR and Advanced Gene Editing Technologies
6.5.2 Expansion of Non-Viral Vectors and Allogeneic Therapies
6.5.3 Integration of AI for Enhanced Efficiency in Development and Manufacturing
6.6 Impact of Drivers and Restraints:
7. Asia Pacific Cell and Gene Therapy Market Analysis
7.1 Asia Pacific Cell and Gene Therapy Market Revenue (US$ Million), 2021–2031
7.2 Asia Pacific Cell and Gene Therapy Market Forecast and Analysis
8. Asia Pacific Cell and Gene Therapy Market Analysis – by Type
8.1 Cell Therapy
8.1.1 Overview
8.1.2 Cell Therapy: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
8.1.2.1 Allogeneic
8.1.2.1.1 Overview
8.1.2.1.2 Allogeneic: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
8.1.2.2 Autologous
8.1.2.2.1 Overview
8.1.2.2.2 Autologous: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
8.1.2.3 Viral Vectors
8.1.2.3.1 Overview
8.1.2.3.2 Viral Vectors: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Gene Therapy
8.2.1 Overview
8.2.2 Gene Therapy: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
8.2.2.1 Non-viral Vectors
8.2.2.1.1 Overview
8.2.2.1.2 Non-viral Vectors: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
8.2.2.2 Viral Vectors
8.2.2.2.1 Overview
8.2.2.2.2 Viral Vectors: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
9. Asia Pacific Cell and Gene Therapy Market Analysis – by Service
9.1 Process Development
9.1.1 Overview
9.1.2 Process Development: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
9.2 cGMP Manufacturing
9.2.1 Overview
9.2.2 cGMP Manufacturing: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Regulatory Services
9.3.1 Overview
9.3.2 Regulatory Services: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Bioassay Services
9.4.1 Overview
9.4.2 Bioassay Services: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
10. Asia Pacific Cell and Gene Therapy Market Analysis – by Scale
10.1 Pre-commercial or R and D Manufacturing
10.1.1 Overview
10.1.2 Pre-commercial or R and D Manufacturing: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Commercial Scale Manufacturing
10.2.1 Overview
10.2.2 Commercial Scale Manufacturing: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
11. Asia Pacific Cell and Gene Therapy Market Analysis – by Service Providers
11.1 CDMOs
11.1.1 Overview
11.1.2 CDMOs: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
11.2 CMOs
11.2.1 Overview
11.2.2 CMOs: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
12. Asia Pacific Cell and Gene Therapy Market Analysis – by Transfection Reagents
12.1 Polymer-based Transfection Reagents
12.1.1 Overview
12.1.2 Polymer-based Transfection Reagents: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
12.2 Lipid-based Transfection Reagents
12.2.1 Overview
12.2.2 Lipid-based Transfection Reagents: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
12.3 Viral Transduction Enhancers
12.3.1 Overview
12.3.2 Viral Transduction Enhancers: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
12.4 Other Transfection Reagents
12.4.1 Overview
12.4.2 Other Transfection Reagents: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
13. Asia Pacific Cell and Gene Therapy Market Analysis – by End User
13.1 Contract Research Organizations
13.1.1 Overview
13.1.2 Contract Research Organizations: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
13.2 Pharmaceutical and Biopharmaceutical Companies
13.2.1 Overview
13.2.2 Pharmaceutical and Biopharmaceutical Companies: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
13.3 Academic and Research Institutes
13.3.1 Overview
13.3.2 Academic and Research Institutes: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14. Asia Pacific Cell and Gene Therapy Market – Country Analysis
14.1 Asia Pacific
14.1.1 Asia Pacific Cell and Gene Therapy Market Breakdown by Countries
14.1.1.1 Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.1.1.1 Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.1.1.2 Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.1.2 Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.1.3 Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.1.4 Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.1.5 Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.1.6 Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2 Asia Pacific Cell and Gene Therapy Market Revenue and Forecast and Analysis – by Country
14.1.2.1 China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.1.1 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.1.1.1 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.1.1.2 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.1.2 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.1.3 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.1.4 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.1.5 China: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.1.6 China: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.2 India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.2.1 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.2.1.1 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.2.1.2 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.2.2 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.2.3 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.2.4 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.2.5 India: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.2.6 India: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.3 South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.3.1 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.3.1.1 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.3.1.2 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.3.2 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.3.3 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.3.4 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.3.5 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.3.6 South Korea: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.4 Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.4.1 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.4.1.1 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.4.1.2 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.4.2 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.4.3 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.4.4 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.4.5 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.4.6 Japan: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.5 Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.5.1 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.5.1.1 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.5.1.2 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.5.2 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.5.3 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.5.4 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.5.5 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.5.6 Singapore: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.6 Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.6.1 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.6.1.1 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.6.1.2 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.6.2 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.6.3 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.6.4 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.6.5 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.6.6 Australia: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.7 Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.7.1 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.7.1.1 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.7.1.2 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.7.2 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.7.3 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.7.4 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.7.5 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.7.6 Malaysia: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.8 Thailand: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.8.1 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.8.1.1 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.8.1.2 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.8.2 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.8.3 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.8.4 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.8.5 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.8.6 Thailand: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.9 Philippines: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.9.1 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.9.1.1 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.9.1.2 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.9.2 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.9.3 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.9.4 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.9.5 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.9.6 Philippines: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.10 Vietnam: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.10.1 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.10.1.1 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.10.1.2 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.10.2 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.10.3 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.10.4 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.10.5 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.10.6 Vietnam: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
14.1.2.11 Rest of APAC: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
14.1.2.11.1 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Type
14.1.2.11.1.1 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Cell Therapy by Type
14.1.2.11.1.2 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Gene Therapy by Type
14.1.2.11.2 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Service
14.1.2.11.3 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Scale
14.1.2.11.4 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Service Providers
14.1.2.11.5 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by Transfection Reagents
14.1.2.11.6 Rest of APAC: Asia Pacific Cell and Gene Therapy Market Breakdown by End User
15. Asia Pacific Cell and Gene Therapy Market Industry Landscape
15.1 Overview
15.2 Product Launch, Product Approvals
15.3 Expansions, Collaboration, Merger and Acquisitions, And Other Strategic Developments
16. Company Profiles
16.1 WuXi AppTec Co Ltd
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Lonza Group AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Syngene International Ltd
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Novotech
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 SK pharmteco Inc
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 CMIC Group
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
16.7 Samsung Biologics Co Ltd
16.7.1 Key Facts
16.7.2 Business Description
16.7.3 Financial Overview
16.7.4 SWOT Analysis
16.7.5 Key Developments
16.8 AGC Biologics AS
16.8.1 Key Facts
16.8.2 Business Description
16.8.3 Products and Services
16.8.4 Financial Overview
16.8.5 SWOT Analysis
16.8.6 Key Developments
16.9 GenScript Biotech Corporation
16.9.1 Key Facts
16.9.2 Business Description
16.9.3 Products and Services
16.9.4 Financial Overview
16.9.5 SWOT Analysis
16.9.6 Key Developments
16.10 Porton Pharma Solutions Ltd
16.10.1 Key Facts
16.10.2 Business Description
16.10.3 Products and Services
16.10.4 Financial Overview
16.10.5 SWOT Analysis
16.10.6 Key Developments
16.11 Lotte Biologics Co Ltd
16.11.1 Key Facts
16.11.2 Business Description
16.11.3 Products and Services
16.11.4 Financial Overview
16.11.5 SWOT Analysis
16.11.6 Key Developments
16.12 Minaris Advanced Therapies
16.12.1 Key Facts
16.12.2 Business Description
16.12.3 Products and Services
16.12.4 Financial Overview
16.12.5 SWOT Analysis
16.12.6 Key Developments
16.13 Cell Therapies Pty Ltd
16.13.1 Key Facts
16.13.2 Business Description
16.13.3 Products and Services
16.13.4 Financial Overview
16.13.5 SWOT Analysis
16.13.6 Key Developments
16.14 Esco Aster Pte. Ltd.
16.14.1 Key Facts
16.14.2 Business Description
16.14.3 Products and Services
16.14.4 Financial Overview
16.14.5 SWOT Analysis
16.14.6 Key Developments
16.15 Aurigene Pharmaceutical Services
16.15.1 Key Facts
16.15.2 Business Description
16.15.3 Products and Services
16.15.4 Financial Overview
16.15.5 SWOT Analysis
16.15.6 Key Developments
16.16 GC Biopharma
16.16.1 Key Facts
16.16.2 Business Description
16.16.3 Products and Services
16.16.4 Financial Overview
16.16.5 SWOT Analysis
16.16.6 Key Developments
16.17 TEIJIN CDMO
16.17.1 Key Facts
16.17.2 Business Description
16.17.3 Products and Services
16.17.4 Financial Overview
16.17.5 SWOT Analysis
16.17.6 Key Developments
16.18 CellVec Pte Ltd
16.18.1 Key Facts
16.18.2 Business Description
16.18.3 Products and Services
16.18.4 Financial Overview
16.18.5 SWOT Analysis
16.18.6 Key Developments
16.19 Avance Clinical Pty Ltd
16.19.1 Key Facts
16.19.2 Business Description
16.19.3 Products and Services
16.19.4 Financial Overview
16.19.5 SWOT Analysis
16.19.6 Key Developments
16.20 Hilleman Laboratories
16.20.1 Key Facts
16.20.2 Business Description
16.20.3 Products and Services
16.20.4 Financial Overview
16.20.5 SWOT Analysis
16.20.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
List of Tables
Table 1. Asia Pacific Cell and Gene Therapy Market Segmentation
Table 2. List of Service Providers
Table 3. List of Potential Customers
Table 4. List of Patents and Description
Table 5. List of Regulatory Bodies and Organizations
Table 6. Import-Export Value of Products Falling Under HS Code 300290: Human Blood; Animal Blood Prepared for Therapeutic, Prophylactic or Diagnostic Uses
Table 7. Heat Map Analysis by Key Players
Table 8. Company Market Share (%) Analysis by Top 5 Players, 2024
Table 9. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Table 10. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 11. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 12. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 13. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 14. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 15. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 16. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 17. Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 18. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 19. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 20. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 21. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 22. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 23. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 24. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 25. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 26. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 27. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 28. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 29. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 30. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 31. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 32. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 33. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 34. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 35. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 36. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 37. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 38. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 39. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 40. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 41. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 42. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 43. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 44. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 45. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 46. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 47. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 48. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 49. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 50. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 51. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 52. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 53. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 54. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 55. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 56. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 57. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 58. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 59. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 60. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 61. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 62. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 63. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 64. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 65. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 66. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 67. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 68. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 69. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 70. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 71. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 72. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 73. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 74. Thailand: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 75. Thailand: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 76. Thailand: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 77. Thailand: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 78. Thailand: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 79. Thailand: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 80. Thailand: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 81. Thailand: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 82. Philippines: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 83. Philippines: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 84. Philippines: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 85. Philippines: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 86. Philippines: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 87. Philippines: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 88. Philippines: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 89. Philippines: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 90. Vietnam: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 91. Vietnam: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 92. Vietnam: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 93. Vietnam: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 94. Vietnam: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 95. Vietnam: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 96. Vietnam: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 97. Vietnam: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 98. Rest of APAC: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Type
Table 99. Rest of APAC: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Cell Therapy by Type
Table 100. Rest of APAC: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Gene Therapy by Type
Table 101. Rest of APAC: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service
Table 102. Rest of APAC: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Scale
Table 103. Rest of APAC: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Service Providers
Table 104. Rest of APAC: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by Transfection Reagents
Table 105. Rest of APAC: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 106. Glossary of Terms, Asia Pacific Cell and Gene Therapy Market
List of Figures
Figure 1. Asia Pacific Cell and Gene Therapy Market Segmentation, by Country
Figure 2. Porter's Five Forces Analysis
Figure 3. PEST Analysis
Figure 4. Company Market Share Analysis, 2024
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Asia Pacific Cell and Gene Therapy Market Revenue (US$ Million), 2021–2031
Figure 7. Asia Pacific Cell and Gene Therapy Market Share (%) – by Type, 2024 and 2031
Figure 8. Cell Therapy: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 9. Allogeneic: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 10. Autologous: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 11. Viral Vectors: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 12. Gene Therapy: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 13. Non-viral Vectors: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 14. Viral Vectors: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 15. Asia Pacific Cell and Gene Therapy Market Share (%) – by Service, 2024 and 2031
Figure 16. Process Development: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 17. cGMP Manufacturing: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 18. Regulatory Services: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 19. Bioassay Services: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 20. Asia Pacific Cell and Gene Therapy Market Share (%) – by Scale, 2024 and 2031
Figure 21. Pre-commercial or R and D Manufacturing: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 22. Commercial Scale Manufacturing: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 23. Asia Pacific Cell and Gene Therapy Market Share (%) – by Service Providers, 2024 and 2031
Figure 24. CDMOs: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 25. CMOs: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 26. Asia Pacific Cell and Gene Therapy Market Share (%) – by Transfection Reagents, 2024 and 2031
Figure 27. Polymer-based Transfection Reagents: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 28. Lipid-based Transfection Reagents: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 29. Viral Transduction Enhancers: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 30. Other Transfection Reagents: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 31. Asia Pacific Cell and Gene Therapy Market Share (%) – by End User, 2024 and 2031
Figure 32. Contract Research Organizations: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 33. Pharmaceutical and Biopharmaceutical Companies: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 34. Academic and Research Institutes: Asia Pacific Cell and Gene Therapy Market– Revenue and Forecast to 2031 (US$ Million)
Figure 35. Asia Pacific Cell and Gene Therapy Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 36. China: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Figure 37. India: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Figure 38. South Korea: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Figure 39. Japan: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Figure 40. Singapore: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Figure 41. Australia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Figure 42. Malaysia: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Figure 43. Thailand: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Figure 44. Philippines: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Figure 45. Vietnam: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Figure 46. Rest of APAC: Asia Pacific Cell and Gene Therapy Market – Revenue and Forecast to 2031 (US$ Million)
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For